Tigercat Pharma Results From A Regional Partnership For CMEA's Velocity
This article was originally published in The Pink Sheet Daily
The asset-focused operator of virtual biotechs teamed with Texas early-stage investment group Remeditex to back a new entity. Tigercat has filed an IND to investigate serlopitant for chronic itching.
You may also be interested in...
In our third annual Life Science VC Survey, those who invest in biopharmaceuticals are feeling good about the IPO window and the helping hand from corporate VCs, and for the third year in a row, they say oncology and rare disease are top investment targets.
Actelion is paying a $25 million upfront for an option to acquire Ceptaris Therapeutics, contingent upon the latter’s receiving FDA approval for its only asset, Valchlor, which faces an August PDUFA date. If the deal closes, Ceptaris will receive another $225 million plus milestones from the Swiss-based biotech.
The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.